9vHPV vaccine
Phase 3Completed 0 views this week 0 watching⚡ Active
Interest: 40/100
40
Development Stage
✓
Pre-clinical✓
Phase 1✓
Phase 24
Phase 35
ApprovedIndication / Disease
Papillomavirus Infections
Conditions
Papillomavirus Infections
Trial Timeline
May 17, 2021 → Apr 6, 2024
NCT ID
NCT04772534About 9vHPV vaccine
9vHPV vaccine is a phase 3 stage product being developed by Merck for Papillomavirus Infections. The current trial status is completed. This product is registered under clinical trial identifier NCT04772534. Target conditions include Papillomavirus Infections.
What happened to similar drugs?
4 of 20 similar drugs in Papillomavirus Infections were approved
Approved (4) Terminated (0) Active (16)
Hype Score Breakdown
Clinical
17
Activity
8
Company
15
Novelty
0
Community
0
Clinical Trials (8)
| NCT ID | Phase | Status |
|---|---|---|
| NCT05450705 | Phase 3 | Active |
| NCT05314023 | Phase 3 | Active |
| NCT05285826 | Phase 3 | Active |
| NCT04772534 | Phase 3 | Completed |
| NCT04708041 | Phase 3 | Active |
| NCT04199689 | Phase 3 | Active |
| NCT03546842 | Phase 3 | Completed |
| NCT01651949 | Phase 3 | Completed |
Competing Products
20 competing products in Papillomavirus Infections